Domperidone for the treatment of patients with refractory gastrointestinal symptoms

Brief description of study

The purpose of this study is to allow the use of domperidone by patients with gastrointestinal disorders who have failed standard therapy. An investigational new drug application (IND) for the expanded the use of Domperidone for the treatment of refractory gastrointestinal symptoms for multiple patients in a single center study. Patients will require additional monitoring while taking the drug and will be assessed for symptomatic improvement. Domperidone is used to treat refractory symptoms of gastroparesis, gastroesophageal reflux. Oral domperidone is approved in several countries outside the USA to treat gastroparesis. Domperidone is not approved by the Federal Drug Administration (FDA). However, treatment with domperidone can occur using the FDA investigational new drug (IND) program.


Clinical Study Identifier: s18-01247
Principal Investigator: Rita M. Knotts.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.